Oyster pushes targeted protein degradation into Alzheimer’s disease
Targeted protein degradation has moved quickly from an oncology concept to a broader drug-development strategy, but the brain has remained the hardest place to apply it. The reason is not conceptual. It is chemical. Protein degraders are heterobifunctional molecules, built to bind a disease protein on one end and recruit the cell’s degradation machinery on the other, and that dual function makes them relatively large. In neurology, size becomes a liability at two separate barriers: the intestinal wall and the blood-brain barrier.
Oyster Therapeutics is trying to solve both at once. The London-based company has raised $60 million to advance a platform designed to deliver degraders orally and, after absorption, across the blood-brain barrier for diseases such as Alzheimer’s. Its lead program targets tau, one of the central proteins implicated in Alzheimer’s pathology. The financing arrives as the field continues to test whether direct removal of pathological proteins can be more precise than simply suppressing them upstream.
The company’s premise is unusually practical. Instead of trying to force a single large molecule through biological membranes, Oyster’s platform allows the drug to disassemble into two smaller molecules that can pass through the gut and the blood-brain barrier. Once inside the cell, those components reassemble into the active degrader, which then directs the target protein toward the proteasome for destruction. In cellular terms, the approach uses a mechanism the body already recognizes: tagging unwanted proteins for disposal. The innovation lies in making that chemistry portable enough for the brain.
One sentence captures the bottleneck plainly: most degrader programs have failed on molecular size before they ever reached a patient.
Why tau remains an attractive but difficult target
Tau sits high on the list of Alzheimer’s drug targets because it lacks the kind of active site that classic small-molecule inhibitors typically need. That leaves drug developers with fewer traditional options and explains why alternative modalities have taken the lead. RNA-based therapies are one route. Antisense oligonucleotides and siRNA candidates can reduce tau production at the messenger RNA level, but they tend to lower all tau, including the healthy protein that supports neuronal function. Oyster’s pitch is narrower: target the pathological form while leaving healthy tau intact.
That selectivity matters because tau biology is not binary. Healthy tau helps stabilize neuronal structure, while pathological tau becomes misfolded and aggregates into insoluble deposits seen in Alzheimer’s brains. Oyster says its chemistry is designed to recognize an intermediate conformational state, the version of tau that is changing from normal to disease-associated. If that selectivity holds up in human studies, the drug could avoid the broad suppression that complicates some RNA approaches.
The distinction is biological, not just medicinal.
It also reflects a broader tension in neurodegenerative drug development: the earlier a therapy is intended to be used, the more tolerability, convenience, and target specificity start to matter. In symptomatic Alzheimer’s disease, patients may accept injections or infusions if the benefit is strong enough. In pre-symptomatic disease, when treatment is meant to intercept biology before major cognitive decline appears, an oral therapy becomes much more attractive.
How Oyster’s strategy compares with other tau programs
Other companies are already testing whether tau can be modified directly or indirectly in humans. Biogen’s diranersen, formerly BIIB080, is an antisense oligonucleotide designed to bind the messenger RNA that encodes tau. In May, preliminary Phase 2 results showed reduction in tau and cognitive benefit in patients with early Alzheimer’s disease, but the trial did not meet its main goal of demonstrating a dose response on a rating scale measurement at week 76. Biogen is expected to present new Phase 2 data at the Clinical Trials on Alzheimer’s Disease conference in Boston.
Arrowhead Pharmaceuticals is also in the field with ARO-MAPT, a small interfering RNA therapy intended to silence the tau gene. Interim Phase 1/2 data last month showed deep and durable tau reductions in healthy volunteers, and the study continues with additional data expected in 2027. Those programs reinforce the level of interest around tau, but they also show how different the field’s experiments have become. Some teams are reducing tau production. Oyster is pursuing a more selective form of protein removal after the protein is made and folded into the wrong conformation.
Oral delivery could determine whether brain degraders scale
An oral degrader would carry advantages beyond convenience. Small molecules are generally less expensive to manufacture than RNA medicines, and they are more stable at room temperature. That combination matters for real-world access, especially if Alzheimer’s treatment eventually moves into earlier, broader patient populations. Stable oral dosing could also fit better with the field’s growing interest in treating people who have biological evidence of disease but no symptoms yet.
For that population, route of administration may become a decisive factor. A therapy that requires injections or infusions may struggle to gain acceptance if a safe oral alternative exists. Oyster is betting that accessibility and target precision will matter as much as raw potency. The company’s platform, called SELFTAC, is built around that idea and could potentially extend beyond tau to other proteins implicated in neurodegenerative disease.
Alpha-synuclein is the obvious next candidate. Misfolded forms of that protein are central to Parkinson’s disease, and several biotechs are already pursuing it. Oyster has not disclosed a Parkinson’s program, but the company says the same degradation strategy could apply. Johnson also said the approach could be relevant in cancer, where targeted protein degradation is already more advanced.
New capital, a renamed company, and an unresolved clinical test
The financing round adds new investors and extends the company’s earlier Series A support. 4BIO Capital led the latest round, with participation from Actium Group, CE Ventures, TOHO Ventures, and Eli Lilly. Existing backers Syncona, Oxford Science Enterprise, Mission BioCapital, and MGB Ventures also participated. Alongside the capital raise, the company changed its name from Kesmalea Therapeutics to Oyster Therapeutics.
The new funds are intended to move the tau degrader toward the clinic, though no timeline has been disclosed. That leaves the central question unchanged: whether a degradational strategy can truly overcome the delivery and selectivity barriers that have kept brain-directed protein degraders on the sidelines. Chemistry has now solved part of the problem. Human data will have to show whether the mechanism survives the leap from elegant design to measurable neurologic benefit.